Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins, Peanut food challenge, oral paste “placebo” - Placebo formulation, Soluprick Positive control, 10 mg/ml, Solution for skin-prick test, Viaskin Peanut, Soluprick Negative control, Solution for skin prick test, ALK 762 Jordnød, Opløsning til priktest (Soluprick), Nøddeallergen, The DBV712 Placebo Patch is the same system as DBV712 250 mcg Patch but without peanut proteins, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut
DBV Technologies
Peanut allergy
1 trial -
Peer Mentoring Intervention for HCV-Infected IDUs
BRIGHT MINDS BIOSCIENCES INC.
Hepatitis C
1 trial -
Peficitinib
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rheumatoid Arthritis (RA)
1 trial -
Peg interferon alpha-2b
Universal Integrated
Hepatitis C
1 trial -
PegIntron (peginterferon alfa-2b)
Universal Integrated
Hepatitis C, Chronic
1 trial -
Pegcetacoplan
Apellis Europe B.V.
Paroxysmal Nocturnal Hemoglobinuria
2 trials -
Pegtibatinase
Travere Therapeutics
Homocystinuria
3 trials -
Pegtibatinase, 0.9 % sodium chloride saline solution (NaCL)
Travere Therapeutics
Classical Homocystinuria
1 trial -
Pegunigalsidase alfa
Protalix BioTherapeutics
Fabry Disease
1 trial -
Pegvaliase
BioMarin Pharmaceutical Australia Pty Ltd
Phenylketonuria (PKU)
2 trials -
Pegylated Interferon Alfa 2a
Vertex Pharmaceuticals (Australia) Pty.
Hepatitis C
1 trial -
Pegylated Interferon Alfa-2a
Hoffmann-La Roche
Chronic Myelogenous Leukemia
1 trial -
Pelacarsen
Novartis Pharmaceuticals
Atherosclerotic Cardiovascular Disease (ASCVD)
1 trial -
Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung
Incyte
Cholangiocarcinoma
1 trial -
Pembrolizumab
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
Pembrolizumab 25 MG/ML [Keytruda]
United Therapeutics Europe Ltd
Lung Cancer, Nonsmall Cell
1 trial -
Pemetrexed
Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
1 trial -
Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, TAGRISSO 40 mg film-coated tablets, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, CARBO-cell® 10 mg/ml Infusionslösung, Konzentrat zur Herstellung einer Infusionslösung, ALIMTA 100 mg powder for concentrate for solution for infusion, Cisplatine Teva 1 mg/ml concentraat voor oplossing voor infusie., Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
Pentoxifylline
United Therapeutics Europe Ltd
Kidney Failure, Chronic
1 trial -
Phase 1: Olanzapine
Shanghai Mental Health Center
Schizophrenia
1 trial -
Phase III Randomized, Open-Label, Multicenter Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination with Lenalidomide in Comparison to Rituximab in Combination with Lenalidomide with a Non-Randomized, Single Arm US Extension of Mosunetuzumab in Combination with Lenalidomide in Patients with Follicular Lymphoma After at Least One Line of Systemic Therapy
Hoffmann-La Roche
Relapsed/refractory follicular lymphoma
1 trial -
Phenazopyridine Hydrochloride
Amneal Pharma Europe Ltd
Pain
1 trial -
Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Herceptin 600 mg solution for injection in vial, Phesgo 600 mg/600 mg solution for injection, Herceptin 150 mg powder for concentrate for solution for infusion
Hoffmann-La Roche
HER2-POSITIVE EARLY BREAST CANCER
1 trial -
Phesgo 1200 mg/600 mg solution for injection, Perjeta 420 mg concentrate for solution for infusion, Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1 200 mg concentrate for solution for infusion, Phesgo 600 mg/600 mg solution for injection
Fondazione Telethon ETS
Invasive Breast Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources